# 2025-08443: FDA Sets OMVOH Review Dates for a Possible Patent Extension

2025-08443, Determination of Regulatory Review Period for Purposes of Patent Extension; OMVOH, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-14 (as of 2026-10-20).

- Canonical: https://policyrisk.com/federal-register/2025-08443
- As of: 2026-10-20
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08443
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; OMVOH
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 20472
- Published: 2025-05-14
- Effective: unknown
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-10-20

## In one line

FDA Sets OMVOH Review Dates for a Possible Patent Extension

## Summary

The FDA has set the official review period for OMVOH, a human biological product, so its patent holder can apply for extra patent time. If anyone thinks the dates are wrong, they have until July 14, 2025, to speak up. Also, folks can challenge whether the company was diligent during the review by November 10, 2025. This helps protect innovation while keeping the process fair and transparent.

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for OMVOH and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08443 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/14/2025-08443/determination-of-regulatory-review-period-for-purposes-of-patent-extension-omvoh)
- [2025-08443 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-14/pdf/2025-08443.pdf)

## Related
- [Previous: 2025-08442, Product Change-Priority Mail Express, Priority Mail, and USPS Ground Advantage®…](https://policyrisk.com/federal-register/2025-08442)
- [Next: 2025-08444, Product Change-Priority Mail Negotiated Service Agreement](https://policyrisk.com/federal-register/2025-08444)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08443 (as of 2026-10-20).